Beck Mack & Oliver’s CytRx Corp CYTR Stock Holding History

Beck Mack & Oliver’s Portfolio CYTR Stock Details CYTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-33,500	Closed	-$12K	–	195
2022 Q1	$12K	Hold	33,500	–	–	﹤0.01%	191
2021 Q4	$17K	Hold	33,500	–	–	﹤0.01%	205
2021 Q3	$20K	Hold	33,500	–	–	﹤0.01%	213
2021 Q2	$33K	Buy	+33,500	New	+$33K	﹤0.01%	201
2019 Q1	–	Sell	-25,000	Closed	-$11K	–	230
2018 Q4	$11K	Buy	+25,000	New	+$17.3K	﹤0.01%	218

Other funds holding CYTR

CTA

Colonial Trust Advisors Spartanburg, South Carolina $1.29B AUM 19.9% 1-Year Est. Return

FHC

First Heartland Consultants Lake St. Louis, Missouri $1.55B AUM 20.5% 1-Year Est. Return

Beck Mack & Oliver's CYTR Position: Q2 2022 in Review

Beck Mack & Oliver sold out of CytRx Corp (CYTR) in Q2 2022, closing a stake of 33,500 shares — an estimated $12K sold.

Beck Mack & Oliver first reported a position in CYTR in Q4 2018 and held it in 5 quarters. The position peaked at $33K in Q2 2021. 2 funds tracked by Wall St. Rank hold CYTR as of Q2 2022.

Beck Mack & Oliver reported no remaining CytRx Corp position as of Q2 2022 after selling out during the quarter.
Beck Mack & Oliver sold 33,500 CytRx Corp shares in Q2 2022, an estimated $12K.
Beck Mack & Oliver first reported a position in CytRx Corp in Q4 2018 and held it in 5 quarters.
Beck Mack & Oliver's CytRx Corp position peaked at $33K in Q2 2021.
2 funds tracked by Wall St. Rank held CytRx Corp as of Q2 2022.

Based on Beck Mack & Oliver's 13F filing for Q2 2022, filed 12 Aug 2022.